Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

February 7, 2024

Immune-Related Side Effects Associated With Improved Survival in NSCLC

Author(s):

Alex Biese

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

 doctor pointing at lungs. Immune checkpoint inhibitor therapy led to improved overall survvial in some patients with NSCLC.

Immune checkpoint inhibitor therapy was associated with improved overall survival in patients with metastatic non-small cell lung cancer.

Among patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who receive treatment via immune checkpoint inhibitor (ICI) therapy, the development of immune-related side effects has been found by researchers to be associated with improved overall survival (OS; the time that a patient lives following treatment, regardless of disease status).

“Developing an immune-related (side effect) mandating delay or discontinuation of ICI therapy and/or systemic corticosteroids for management of toxic effects was associated with significantly improved median overall survival,” researchers wrote in a study published in JAMA Network Open. “This association was not compromised by hospitalization for management of toxic effects of severe immune-related adverse events.”

Analyzing data from 803 patients with NSCLC who received ICIs between March 1, 2014 and Nov. 30, 2021 in Alberta, Canada captured via the Alberta Immunotherapy Database with median ages of 69.7 and 67.5 and sex distribution of 52.9% women and 49.7% women for patients who did and did not experience immune-related side effects, respectively, researchers found that the median OS for the total study cohort was 15.7 months.

“In the 12-week landmark analysis (of 611 patients),” researchers noted, “developing a clinically meaningful (immune-related side effect) was associated with a significantly longer median OS compared with those patients who did not,” with median OS findings of 23.7 versus 9.8 months, according to the study.

The same analysis found that the development of a clinically meaningful immune-related side effect was associated with a median time of 18 months to the next treatment, compared with 7.3 months until the next treatment for patients who did not experience such a side effect.

Researchers reported that 297 patients were diagnosed with a clinically meaningful immune-related side effect, meaning a side effect that caused a delay in or discontinuation of ICI therapy and/or systematic steroids to manage toxic effects, with a median time to development of 3.4 months and the most common being pneumonitis (inflammation in the lungs, 82 patients), dermatitis (skin swelling and irritation, 63 patients) and colitis (inflammation in the colon, 42 patients).

Additionally, researchers noted the relative frequency of immune-related side effects by type of ICI, with 196 of 509 patients (38.5%) treated with Keytruda (pembrolizumab), 99 of 280 (35.4%) treated with Opdivo (nivolumab), one of nine (11.1%) who received Tecentriq (atezolizumab) and 20 of 62 (32.3%) for an ICI combined with chemotherapy. Ninety of 297 patients, or 30.3%, were hospitalized due to the side effects, with 47 of the hospitalized cases, or 52.2%, due to pneumonitis.

Researchers stated that their study was “the largest contemporary clinical dataset examining (immune-related side effects) and survival in locally advanced or metastatic NSCLC.”

“In our cohort, we identified several baseline patient characteristics associated with (immune-related side effect) development: (patients who were) 60 years or older, ECOG performance status 0 (meaning they had no difficulty performing daily tasks independently), high expression of (the protein) PD-L1, absence of bone metastases, DNLR (derived neutrophil-lymphocyte ratio) of 3 or less, and levels of hemoglobin, albumin and LDH (lactate dehydrogenase) within reference range,” researchers wrote. “Other than response to ICI therapy, (immune-related side effect) development was not associated with treatment-related characteristics ([including] ICI agent, ICI alone or in combination with chemotherapy, and treatment line) in our study population.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Related Content
Advertisement
Illustration of lungs.
May 15th 2025

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

Ryan Scott
The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text
May 14th 2025

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

Ryan Scott
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
May 7th 2025

Breaking Barriers: Why Increasing Lung Screening is Critical

Lung Cancer Initiative (LCI)
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
Lung Cancer Initiative has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer: © stock.adobe.com.
May 7th 2025

Lung Cancer Initiative Names New Chief Scientific Officer and Announces 2025 Research Award Recipients

Lung Cancer Initiative (LCI)
LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.
Related Content
Advertisement
Illustration of lungs.
May 15th 2025

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

Ryan Scott
The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text
May 14th 2025

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

Ryan Scott
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
May 7th 2025

Breaking Barriers: Why Increasing Lung Screening is Critical

Lung Cancer Initiative (LCI)
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
Lung Cancer Initiative has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer: © stock.adobe.com.
May 7th 2025

Lung Cancer Initiative Names New Chief Scientific Officer and Announces 2025 Research Award Recipients

Lung Cancer Initiative (LCI)
LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.